IMPORTANT NOTICE: Our email addresses will soon change. Learn more >>

Zombie NIR™ Fixable Viability Kit

Pricing & Availability
Regulatory Status
RUO
Other Names
Fixable Dye, Fixable Viability Dye
Ave. Rating
Submit a Review
Product Citations
publications
Zombie_NIR_Antibody_FC_062413
One day old C57BL/6 mouse splenocytes were stained with Zombie NIR™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie NIR™ staining, are indicated in black.
  • Zombie_NIR_Antibody_FC_062413
    One day old C57BL/6 mouse splenocytes were stained with Zombie NIR™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie NIR™ staining, are indicated in black.
See Zombie NIR™ spectral data
Cat # Size Price Quantity Check Availability Save
423105 100 tests 72€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
423106 500 tests 268€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Zombie NIR™ is an amine reactive fluorescent dye that is non-permeant to live cells, but permeant to the cells with compromised membranes. Thus, it can be used to assess live vs. dead status of mammalian cells. Zombie NIR™ is a polar water soluble dye, providing red fluorescence, making it suitable for multi-color detection.

Product Details
Technical data sheet

Product Details

Preparation
Zombie NIR™ Fixable Viability kit is composed of lyophilized Zombie NIR™ dye and anhydrous DMSO. For reconstitution, bring the kit to room temperature; add 100 µl of DMSO to one vial of Zombie NIR™ dye until fully dissolved. 100 tests = 1 vial of Zombie NIR™ + DMSO, 500 tests = 5 vials of Zombie NIR™ + DMSO.
Storage & Handling
Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie NIR™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.
Application

FC - Quality tested

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis.

For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type.

Excitation Laser
Red Laser (633 nm)
Application Notes

Zombie NIR™ dye is excited by the red laser and has fluorescence emission maximum at 746 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie NIR™ dye has similar emission to APC/Cyanine7.

Standard Cell Staining Protocol:

  1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrofuge to ensure the reagent is at the bottom of the vial.
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie NIR™ dye and mix until fully dissolved
  3. Wash cells with PBS buffer (no Tris buffer and protein free).
  4. Dilute Zombie NIR™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 106 cells in diluted 100 µL Zombie NIR™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µL for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.
    • Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    • Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.
  5. Incubate the cells at room temperature (or 4°C), in the dark, for 15-30 minutes.
  6. Wash one time with 2 mL BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA.
  7. Continue performing antibody staining procedure as desired.
  8. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation.

No-wash Sequential Staining Protocol:

  1. Wash cells with PBS buffer (no Tris buffer and protein free).
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie NIR™ dye and mix until fully  dissolved
  3. Determine the total µL volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µL. Subtract that antibody volume from the 100 µL total staining volume intended for the assay. In the remaining volume, dilute Zombie NIR™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µL of antibody cocktail for a 100 µL total staining volume, use 80 µL of Zombie NIR™ solution. Resuspend 1-10 x 106 cells in the appropriate volume of Zombie NIR™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.
    • Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    • Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.
  4. Incubate for 10-15 minutes at RT (or 4°C), protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes.
  5. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet.
  6. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells.
    • Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie NIR™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie NIR™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie NIR™.
Additional Product Notes

View more applications data for this product in our Scientific Poster Library.

Application References

(PubMed link indicates BioLegend citation)
  1. McMaster SR, et al. 2015. PLoS One. 10:115725. PubMed
  2. Prado-Garcia H, et al. 2015. Anticancer Res.35:1529. PubMed
  3. Rodriguez-Rodriguez N, et al. 2015. J Immunol. 194:4207. PubMed
  4. Flies DB, et al. 2015. J Immunol. 194:5294. PubMed
Product Citations
  1. Headley M, et al. 2016. Nature. 531:513-517. PubMed
  2. Rad S M AH, et al. 2020. PLoS One. 15:e0232915. PubMed
  3. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  4. Wu R, et al. 2022. J Dermatol. 49:432. PubMed
  5. Wang W, et al. 2022. Dev Cell. 57:228. PubMed
  6. Chaurio RA, et al. 2022. Immunity. 55:115. PubMed
  7. Cautivo KM, et al. 2022. Immunity. 55:254. PubMed
  8. Kuloglu ZE, et al. 2022. Allergy. 77:2459. PubMed
  9. Bayley R, et al. 2022. Mol Cell. 82:1924. PubMed
  10. Rodriguez-Tirado C, et al. 2022. Cancer Res. 82:2313. PubMed
  11. Tang Q, et al. 2022. Mol Ther. 30:2709. PubMed
  12. Gideon HP, et al. 2022. Immunity. 55:827. PubMed
  13. Zhang Y, et al. 2022. Nat Med. 28:1421. PubMed
  14. Sudmeier LJ, et al. 2022. Cell Rep Med. 3:100620. PubMed
  15. Naseem MU, et al. 2022. J Gen Physiol. 154: . PubMed
  16. Vukovic N, et al. 2022. J Biol Chem. 298:102153. PubMed
  17. Berger G, et al. 2022. Proc Natl Acad Sci U S A. 119:e2111003119. PubMed
  18. Hsieh T, et al. 2022. Front Immunol. 13:901030. PubMed
  19. Werder RB, et al. 2022. Sci Adv. 8:eabo6566. PubMed
  20. Zhu Y, et al. 2022. Immunology. 167:576. PubMed
  21. Ostendorf BN, et al. 2022. Nature. 611:346. PubMed
  22. Wang Z, et al. 2022. J Exp Med. 219: . PubMed
  23. Naranjo S, et al. 2022. Genes Dev. 36:936. PubMed
  24. Buckner CM, et al. 2022. Cell. 185:4333. PubMed
  25. VanDyke D, et al. 2022. Cell Rep. 41:111478. PubMed
  26. Wang W, et al. 2022. Cell Rep. 41:111582. PubMed
  27. Ogishi M, et al. 2023. J Exp Med. 220: . PubMed
  28. Zhu H, et al. 2023. Clin Transl Radiat Oncol. 38:138. PubMed
  29. Schaefer-Babajew D, et al. 2023. Nature. 613:735. PubMed
  30. Edwards SC, et al. 2023. J Exp Med. 220: . PubMed
  31. Naylor G, et al. 2022. Cancers (Basel). 14: . PubMed
  32. Ronning KE, et al. 2022. J Neuroinflammation. 19:299. PubMed
  33. Pleuger C, et al. 2022. Elife. 11: . PubMed
  34. Dutt TS, et al. 2022. Cell Rep. 41:111783. PubMed
  35. Xu Q, et al. 2023. Nat Immunol. 24:186. PubMed
  36. Hägglöf T, et al. 2023. Cell. 186:147. PubMed
  37. Schepers M, et al. 2023. Brain Behav Immun. 109:1. PubMed
  38. Gauthier L, et al. 2023. Nat Biotechnol. :. PubMed
  39. Ali LR, et al. 2023. J Exp Med. 220: . PubMed
  40. Zhou H, et al. 2023. Front Immunol. 13:1059687. PubMed
  41. Vyas M, et al. 2023. Front Immunol. 13:1098445. PubMed
  42. Rosain J, et al. 2023. Cell. 186:621. PubMed
  43. Ernst MPT, et al. 2023. Hemasphere. 7:e824. PubMed
  44. Babl N, et al. 2023. Front Oncol. 13:1107484. PubMed
  45. Dragan M, et al. 2022. J Invest Dermatol. 142:583. PubMed
  46. Parida PK, et al. 2022. Cell Metab. 34:90. PubMed
  47. Ma Y, et al. 2022. Am J Physiol Heart Circ Physiol. 322:H622. PubMed
  48. Salmon AJ, et al. 2022. Cancer Immunol Res. 10:597. PubMed
  49. Nelson LJ, et al. 2022. Cell Cycle. 21:1103. PubMed
  50. Kania AK, et al. 2022. J Immunol. 208:1873. PubMed
  51. Xu Y, et al. 2022. Bio Protoc. 12:e4354. PubMed
  52. McCafferty S, et al. 2022. Mol Ther. 30:2968. PubMed
  53. Pandey SP, et al. 2022. Cell Host Microbe. 30:1003. PubMed
  54. Knelson EH, et al. 2022. Cancer Immunol Res. 10:947. PubMed
  55. Sun Y, et al. 2022. STAR Protoc. 3:101479. PubMed
  56. Edwards KJ, et al. 2022. Cancer Immunol Res. 10:1084. PubMed
  57. Park G, et al. 2023. Photochem Photobiol. 99:850. PubMed
  58. Zhao Y, et al. 2022. J Neurosci. . PubMed
  59. Lutz EA, et al. 2022. Proc Natl Acad Sci U S A. 119:e2205983119. PubMed
  60. Sauter M, et al. 2022. STAR Protoc. 3:101664. PubMed
  61. Terminel MN, et al. 2022. BMC Neurosci. 23:58. PubMed
  62. Tan GMY, et al. 2022. Cancers (Basel). 14:. PubMed
  63. Prochazka L, et al. 2022. Mol Syst Biol. 18:e10886. PubMed
  64. Egli J, et al. 2022. MAbs. 14:2143009. PubMed
  65. Han X, et al. 2022. Nutrients. 14:. PubMed
  66. Li Y, et al. 2023. Adv Mater. 35:e2208923. PubMed
  67. Schönberger K, et al. 2023. Anal Chem. 95:4325. PubMed
  68. Tschanz F, et al. 2021. Cancer Res Commun. 1:164. PubMed
  69. Liu HJ, et al. 2023. Nat Commun. 14:1214. PubMed
  70. Tan J, et al. 2023. Acta Pharm Sin B. 13:632. PubMed
  71. Muri J, et al. 2023. Nat Immunol. 24:604. PubMed
  72. Zhou P, et al. 2023. Immunity. 56:669. PubMed
  73. Ananya A, et al. 2023. Immun Ageing. 20:10. PubMed
  74. Pasqual G, et al. 2023. Methods Mol Biol. 2618:71. PubMed
  75. Luo X, et al. 2023. Methods Mol Biol. 2618:133. PubMed
  76. Jiang X, et al. 2023. J Clin Invest. 133:. PubMed
  77. Pankhurst TE, et al. 2023. Cell Rep. 42:112310. PubMed
  78. Martins Nascentes Melo L, et al. 2023. J Immunother Cancer. 11:. PubMed
  79. Zhang YN, et al. 2023. Nat Commun. 14:1985. PubMed
  80. Onyshchenko K, et al. 2023. Nat Commun. 14:2087. PubMed
  81. Xu Z, et al. 2023. Cancers (Basel). 15:. PubMed
  82. Liu L, et al. 2023. J Exp Clin Cancer Res. 42:85. PubMed
  83. Glasner A, et al. 2023. Nat Immunol. 24:1020. PubMed
  84. Sugita M, et al. 2023. Cell Death Dis. 14:305. PubMed
  85. Lee K, et al. 2023. JCI Insight. 8:. PubMed
  86. Gao Y, et al. 2023. iScience. 26:106729. PubMed
  87. Changsheng H, et al. 2023. Sci Adv. 9:eade4186. PubMed
  88. Villalba N, et al. 2023. J Neuroinflammation. 20:127. PubMed
  89. Meckler JF, et al. 2023. Cancer Immunol Immunother. . PubMed
  90. Imai H, et al. 2023. iScience. 26:106822. PubMed
  91. Braun DJ, et al. 2023. PLoS One. 18:e0286495. PubMed
  92. Zhang TR, et al. 2023. Pharmaceuticals (Basel). 16:. PubMed
  93. Li JD, et al. 2023. Front Immunol. 14:1186393. PubMed
  94. Wu L, et al. 2023. Cell Res. . PubMed
  95. Cansever D, et al. 2023. Nat Immunol. . PubMed
  96. Liu X, et al. 2023. J Neuroinflammation. 20:144. PubMed
  97. Liu Y, et al. 2022. Signal Transduct Target Ther. 7:347. PubMed
  98. Kim MY, et al. 2021. JCI Insight. 6:. PubMed
  99. Martínez-Vélez N, et al. 2022. Mol Cancer Ther. 21:471. PubMed
  100. Baratchart E, et al. 2022. PLoS Comput Biol. 18:e1009839. PubMed
  101. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  102. Rosina M, et al. 2022. Cell Metab. 34:533. PubMed
  103. Hsu MA, et al. 2022. Cancer Immunol Immunother. :. PubMed
  104. Zheng J, et al. 2022. Front Pharmacol. 13:866228. PubMed
  105. Wang L, et al. 2020. Front Cell Dev Biol. 0.745138889. PubMed
  106. Iyer S, et al. 2021. Cancer Discov. 0.725. PubMed
  107. Montes de Oca M, et al. 2016. Cell Rep. 17:399-412. PubMed
  108. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  109. Gibb D, et al. 2016. EBioMedicine. 9: 77-86. PubMed
  110. Kallemeijn WW, et al. 2019. Cell Chem Biol. 26:892. PubMed
  111. Kollareddy M, et al. 2017. Cancer Lett. 10.1016/j.canlet.2017.05.027. PubMed
  112. Ajoge HO, et al. 2022. Viruses. 14:. PubMed
  113. Tan L, et al. 2022. Biochem Biophys Rep. 32:101351. PubMed
  114. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  115. He C, et al. 2022. Sci Adv. 8:eabm4552. PubMed
  116. Otano I, et al. 2021. Nat Commun. 12:7296. PubMed
  117. Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed
  118. Landry LG, et al. 2021. Bio Protoc. 11:e3883. PubMed
  119. Barros-Martins J, et al. 2021. Nat Med. 27:1525. PubMed
  120. Nordengrün M, et al. 2021. Front Immunol. 12:651060. PubMed
  121. Roberts A, et al. 2021. Sci Rep. 11:4030. PubMed
  122. Ma Q, et al. 2021. Clin Transl Immunology. 10:e1300. PubMed
  123. Sheikh BN, et al. 2020. Nat Cell Biol. 22:828. PubMed
  124. Pathak JL, et al. 2021. Front Cell Dev Biol. 628139:9. PubMed
  125. Jiang C, et al. 2020. Int J Biol Sci. 2.802083333. PubMed
  126. Qiu J, et al. 2020. Cell Rep. 33:108465. PubMed
  127. Sagami S, et al. 2017. PLoS One. 10.1371/journal.pone.0169681. PubMed
  128. Lentucci C, et al. 2017. J Biol Chem. 292:2754-2772. PubMed
  129. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  130. Kilens S, et al. 2018. Nat Commun. 9:360. PubMed
  131. Merz SF, et al. 2019. Nat Commun. 10:2312. PubMed
  132. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  133. Karlen SJ, et al. 2018. J Neuroinflammation. 15:344. PubMed
  134. Vishnoi M, et al. 2018. Cancer Res. 78:5349. PubMed
  135. Abou-Hamad J, et al. 2022. iScience. 25:105524. PubMed
  136. Sauter M, et al. 2022. iScience. 25:103677. PubMed
  137. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  138. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  139. Sneller MC, et al. 2022. Nature. 606:375. PubMed
  140. Hamminger P, et al. 2021. J Autoimmun. 119:102610. PubMed
  141. Hu W, et al. 2021. Nat Immunol. 22:1163. PubMed
  142. Schalbetter SM, et al. 2022. Sci Adv. 8:eabi6672. PubMed
  143. Jimenez-Duran G, et al. 2020. EBioMedicine. 61:103039. PubMed
  144. Li JY, et al. 2020. J Clin Invest. 130:1767. PubMed
  145. AC Belkina, JE Snyder-Cappione 2017. Cytometry A. 91:175-179. PubMed
  146. Kodumudi KN, et al. 2019. Front Immunol. 10:1939. PubMed
  147. Liu HJ, et al. 2018. JCI Insight. 3. PubMed
  148. Zou L, et al. 2022. Brain Behav Immun. 100:10. PubMed
  149. Son ET, et al. 2021. J Clin Invest. 131:. PubMed
  150. Majstrowicz K, et al. 2021. J Cell Sci. 134:. PubMed
  151. Daniel S, et al. 2021. Infect Immun. 89:e0016521. PubMed
  152. van der Heide V, et al. 2022. Cell Rep. :110508. PubMed
  153. Michaud D, et al. 2022. Front Immunol. 12:745873. PubMed
  154. Nagatake T, et al. 2022. Mucosal Immunol. 15:289. PubMed
  155. Watters JM, et al. 2021. Biochem Biophys Res Commun. 534:773. PubMed
  156. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  157. Agudelo M, et al. 2021. J Exp Med. :218. PubMed
  158. Gaebler C, et al. 2021. Nature. 639:591. PubMed
  159. Olingy C, et al. 2017. Sci Rep. 10.1038/s41598-017-00477-1. PubMed
  160. Bouffi C, et al. 2015. J Immunol. 195: 2683-2695. PubMed
  161. Higuchi T, et al. 2015. Cancer Immunol Res. 3: 1257 - 1268. PubMed
  162. Weisberg SP, et al. 2020. Cell Reports. 29(12):3916-3932.e5.. PubMed
  163. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  164. García Nores GD, et al. 2018. Nat Commun. 9:1970. PubMed
  165. Verma M, et al. 2018. Cell Stem Cell. 23:530. PubMed
  166. Patricio DO, et al. 2022. Front Immunol. 13:1042463. PubMed
  167. Halim L, et al. 2022. Front Immunol. 13:836549. PubMed
  168. Hemkemeyer SA, et al. 2020. J Biol Chem. 296:100136. PubMed
  169. Massafra V, et al. 2021. J Immunol. 207:493. PubMed
  170. Agudelo M, et al. 2022. J Exp Med. 219:. PubMed
  171. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  172. Woodruff MC, et al. 2022. Nature. :. PubMed
  173. Woodruff MC, et al. 2020. Nat Immunol. 1.920833333. PubMed
  174. Xu AQ, et al. 2020. Elife. 9:00. PubMed
  175. Si Y, et al. 2020. Sci Adv. 6:eaba0995. PubMed
  176. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  177. Guarnaccia AD, et al. 2021. Cell Rep. 108636:34. PubMed
  178. Hering L, et al. 2021. Int J Mol Sci. 22:. PubMed
  179. Kienzl M, et al. 2020. Oncoimmunology. 9:1776059. PubMed
  180. Jenkins RW, et al. 2018. Cancer Discov. 8:196. PubMed
  181. Retamal‐Díaz A, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01523. PubMed
  182. Wlodarska M et al. 2017. Cell host & microbe. 22(1):25-37 . PubMed
  183. Beatson RE, et al. 2021. Cell Rep Med. 2:100473. PubMed
  184. Mahmoud W, et al. 2021. Cell Tissue Res. Online ahead of print. PubMed
  185. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  186. Ostendorf BN, et al. 2020. Nat Med. 26:1048. PubMed
  187. Akiyama H, et al. 2020. J Virol. . PubMed
  188. Sperber HS, et al. 2020. FASEB J. 14615:34. PubMed
  189. Moreau GB, et al. 2020. Am J Trop Med Hyg. 103:1215. PubMed
  190. Simonneau M, et al. 2018. Oncotarget. 9:36457. PubMed
  191. Koizumi SI, et al. 2018. Nat Commun. 9:5344. PubMed
  192. Rao X, et al. 2022. Cell Death Dis. 13:891. PubMed
  193. Miller EB, et al. 2021. J Neuroinflammation. 18:235. PubMed
  194. Mills C, et al. 2022. Cells. 11:. PubMed
  195. Pettinato G, et al. 2021. Sci Adv. 7:. PubMed
  196. Godoy-Pacheco A, et al. 2022. Oncol Lett. 24:288. PubMed
  197. Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed
  198. Michaud D, et al. 2020. Cytokine. 125:154817. PubMed
  199. PRADO-GARCIA H, et al. 2015. Anticancer Res. 35:1529. PubMed
  200. Lisk C, et al. 2020. Front Immunol. 1.329166667. PubMed
  201. Yang S, et al. 2019. Nat Commun. 10:2782. PubMed
  202. Casella G, et al. 2017. Sci Rep. . 10.1038/s41598-017-16702-w. PubMed
  203. Adamik J, et al. 2022. Nat Commun. 13:5184. PubMed
  204. Sodji QH, et al. 2022. Cancer Res Commun. 2:725. PubMed
  205. Zhang Z, et al. 2021. Acta Pharm Sin B. 11:1965. PubMed
  206. Mahadevan NR, et al. 2021. Cancer Discov. 11:1952. PubMed
  207. Alansary M, et al. 2021. Dent Traumatol. 37:90. PubMed
  208. Le X, et al. 2021. J Thorac Oncol. 16:583. PubMed
  209. Song D, et al. 2021. Sci Rep. 11:22966. PubMed
  210. Aires V, et al. 2021. Front Immunol. 12:684430. PubMed
  211. Choi JE, et al. 2021. Nat Metab. 3:182. PubMed
  212. Ajina R, et al. 2021. Cancer Immunol Res. 9:386. PubMed
  213. Sato R, et al. 2020. Int Immunol. 499:32. PubMed
  214. Aregger M, et al. 2020. Nat Metab. 0.429861111. PubMed
  215. Alshetaiwi H, et al. 2020. Sci Immunol. 5:00. PubMed
  216. Steinbach K, et al. 2016. J Exp Med. 213: 1571 - 1587. PubMed
  217. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  218. Grandclaudon M, et al. 2019. Cell. 179:432. PubMed
  219. Wang K, et al. 2018. Medicine (Baltimore). 97:e0710. PubMed
  220. Li Y, et al. 2022. J Neuroinflammation. 19:261. PubMed
  221. Thyrsted J, et al. 2021. iScience. 24:103300. PubMed
  222. Basu A, et al. 2021. Cancer Immunol Res. Online ahead of print. PubMed
  223. Viant C, et al. 2021. J Exp Med. 218:. PubMed
  224. Nakajima T, et al. 2021. J Exp Med. 218:. PubMed
  225. Jie X, et al. 2022. J Immunother Cancer. 10:. PubMed
  226. Ferrer-Font L, et al. 2021. Curr Protoc. 1:e222. PubMed
  227. Bogie JF, et al. 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed
  228. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  229. Wang Z, et al. 2021. bioRxiv. . PubMed
  230. Littwitz-Salomon E, et al. 2021. Nat Commun. 12:5376. PubMed
  231. Tavazoie MF, et al. 2018. Cell. 172:825. PubMed
  232. English KG, et al. 2022. Biomedicines. 10:. PubMed
  233. Yang J, et al. 2022. Microbiome. 10:149. PubMed
  234. Stinson WA, et al. 2022. JCI Insight. 7:. PubMed
  235. Kim S, et al. 2022. Redox Biol. 54:102347. PubMed
  236. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  237. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  238. Christopher GA, et al. 2021. Biomolecules. 12:. PubMed
  239. Cho A, et al. 2021. Nature. Online ahead of print. PubMed
  240. Clapes T, et al. 2021. Nat Cell Biol. 23:704. PubMed
  241. Woodruff M, et al. 2020. medRxiv. . PubMed
  242. McHugh D, et al. 2020. Life Sci Alliance. 3:00. PubMed
  243. Espinoza J, et al. 2017. Oxidative Medicine and Cellular Longevity. 10.1155/2017/6781872. PubMed
  244. Pinder C, et al. 2017. J Immunol. 10.4049/jimmunol.1701253. PubMed
  245. Liu Y, et al. 2022. Front Oncol. 12:1037934. PubMed
  246. Wan G, et al. 2021. Sci Rep. 11:22121. PubMed
  247. Hills LB, et al. 2021. J Immunol. 206:89. PubMed
  248. Kuhn JA, et al. 2021. Elife. 10:. PubMed
  249. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
  250. Xu Y, et al. 2021. Front Immunol. 12:666991. PubMed
  251. Zhang H, et al. 2021. Cell Rep. 36:109708. PubMed
  252. Zhu S, et al. 2022. J Oncol. 2022:8724933. PubMed
  253. Johnson AM, et al. 2020. J Immunol. 204:2295. PubMed
  254. Thompson EA, et al. 2021. Cell Rep. 108863:34. PubMed
  255. Popay TM, et al. 2021. Elife. 10: . PubMed
  256. Rodríguez-Rodríguez N, et al. 2015. J Immunol. 194:4207. PubMed
  257. Nagatake T, et al. 2018. Int Immunol. 30:471. PubMed
  258. Ito Y, et al. 2018. Cell. 174:636. PubMed
  259. Lim JME, et al. 2022. Cell Rep Med. 3:100793. PubMed
  260. Vanekova L, et al. 2022. Methods Protoc. 5:. PubMed
  261. Elias G, et al. 2022. Elife. 11:. PubMed
  262. Cohen CA, et al. 2021. Nat Commun. 12:4678. PubMed
  263. Scharer CD, et al. 2020. Nat Commun. 3989:11. PubMed
  264. Ruibal P, et al. 2016. Nature. 533: 100-104. PubMed
  265. McGinnis CS, et al. 2019. Nat Methods. 1.096527778. PubMed
  266. Günther T, et al. 2019. PLoS Pathog. 15:e1007838. PubMed
  267. Fujimoto N, et al. 2020. PLoS Biol. 18:e3000704. PubMed
  268. Meyrath M, et al. 2020. Nat Commun. 2.564583333. PubMed
  269. van Vloten JP, et al. 2019. Mol Ther Methods Clin Dev. 13:154. PubMed
  270. Akuffo AA, et al. 2018. J Biol Chem. 293:6187. PubMed
  271. Morganti JM, et al. 2019. J Neuroinflammation. 16:98. PubMed
  272. Jalloh S, et al. 2022. PLoS Pathog. 18:e1010479. PubMed
  273. Cui Z, et al. 2021. Cell Death Dis. 12:775. PubMed
  274. Mudd PA, et al. 2022. Cell. 185:603. PubMed
  275. Valestrand L, et al. 2022. Am J Pathol. . PubMed
  276. Espinal A, et al. 2022. Int J Mol Sci. 23:. PubMed
  277. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  278. Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed
  279. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  280. Hemkemeyer SA, et al. 2020. J Biol Chem. . PubMed
  281. Luo G, et al. 2021. Sci Rep. 11:7841. PubMed
  282. Braun DA, et al. 2021. Cancer Cell. 39:632. PubMed
  283. Tomić A, et al. 2016. PLoS Pathog. 12:e1006015. PubMed
  284. Filiano A, et al. 2016. Nature. 535:425-429. PubMed
  285. Armbruster N, et al. 2016. J Immunol. 196: 1284 - 1292. PubMed
  286. Ramachandran P, et al. 2019. Nature. 575:512. PubMed
  287. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
  288. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  289. Waight JD, et al. 2018. Cancer Cell. 33:1033. PubMed
  290. Tajima M, et al. 2022. Curr Protoc. 2:e540. PubMed
  291. Qadir AS, et al. 2021. iScience. 24:103348. PubMed
  292. Lozano-Ojalvo D, et al. 2021. Cell Rep. 36:109570. PubMed
  293. Dieterle ME, et al. 2021. Elife. 10:. PubMed
  294. Sharma V, et al. 2021. ACR Open Rheumatol. 3:277. PubMed
  295. Clement CC, et al. 2021. Immunity. 54:721. PubMed
  296. Zhang YN, et al. 2021. Sci Adv. 7:eabj3107. PubMed
  297. Manouchehri N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  298. Mohammadi MR, et al. 2021. Commun Biol. 4:685. PubMed
  299. Noort RJ, et al. 2021. Front Cell Dev Biol. 9:659397. PubMed
  300. Soley BDS, et al. 2020. Br J Pharmacol. 177:3535. PubMed
  301. Lo CH, et al. 2021. Sci Rep. 6055:11. PubMed
  302. Salazar Y, et al. 2020. J Clin Invest. 130:3560. PubMed
  303. Bhattacharya P, et al. 2020. Elife. 9:00. PubMed
  304. Grubiši? V, et al. 2020. Cell Rep. 32:108100. PubMed
  305. Shim K, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.023. PubMed
  306. Cloarec R, et al. 2016. PLoS One. 11: 0160176. PubMed
  307. Grajchen E, et al. 2020. J Neuroinflammation. 0.863888889. PubMed
  308. Zhang Y, et al. 2018. Front Microbiol. 9:2967. PubMed
  309. Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed
  310. Su Y, et al. 2021. Clin Cancer Res. :clincanres.2241.2021. PubMed
  311. Dudek M, et al. 2021. Nature. 592:444. PubMed
  312. Jacobsen H, et al. 2021. Nat Commun. 12:4957. PubMed
  313. Cillo AR, et al. 2021. Cell Rep Med. 2:100476. PubMed
  314. Janssen JJE, et al. 2022. Am J Physiol Endocrinol Metab. 322:E141. PubMed
  315. Wang Z, et al. 2022. J Exp Med. 219:. PubMed
  316. He Y, et al. 2022. Cells. 11:. PubMed
  317. Rouleau N, et al. 2020. Immunohorizons. 0.695833333. PubMed
  318. Rizvi F, et al. 2021. Nat Commun. 0.925694444. PubMed
  319. Herland A, et al. 2020. Nat Biomed Eng. 421:4. PubMed
  320. Oherle K, et al. 2020. Immunity. 275:52. PubMed
  321. Wang Z, et al. 2021. Nature. 592:616. PubMed
  322. Ramos MIP, et al. 2021. Elife. 10:. PubMed
  323. McMaster S, et al. 2015. PLoS One. 10:115725. PubMed
  324. Ghezraoui H, et al. 2018. Nature. 560:122. PubMed
  325. Manuszak C, et al. 2020. J Biol Methods. 7:e131. PubMed
  326. McKenzie MD, et al. 2019. Cell Stem Cell. 25:258. PubMed
  327. Zischke J, et al. 2017. PLoS Pathogens. 13(6):e1006454. PubMed
  328. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  329. Tang JS, et al. 2022. Front Immunol. 13:946713. PubMed
  330. Wang Z, et al. 2021. Nature. 595:426. PubMed
  331. Mumby MJ, et al. 2021. J Virol. 95:e0058821. PubMed
  332. Chou TW, et al. 2021. Cell Death Dis. 12:756. PubMed
  333. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  334. Hobbs BE, et al. 2021. Pathogens. 10:. PubMed
  335. Fan ZP, et al. 2021. Front Immunol. 12:743354. PubMed
  336. Lien TS, et al. 2021. Front Immunol. 12:618577. PubMed
  337. Phan TS, et al. 2021. Sci Adv. 7:. PubMed
  338. Luo L, et al. 2021. J Neuroinflammation. 18:27. PubMed
  339. Suzuki T, et al. 2017. Cell Rep. 18(8):2045-2057. PubMed
  340. Flies D, et al. 2015. J Immunol. 194:5294. PubMed
  341. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  342. Daniels M, et al. 2017. Sci Rep.. 10.1038/s41598-017-17387-x. PubMed
  343. Chou DB, et al. 2022. Nat Commun. 13:6021. PubMed
  344. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
  345. Denoth-Lippuner A, et al. 2021. Cell Stem Cell. 28:2020. PubMed
  346. Zhang Y, et al. 2022. Mater Today Bio. 15:100317. PubMed
  347. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  348. Madsen CS, et al. 2022. Commun Biol. 5:888. PubMed
  349. Maas RR, et al. 2021. Nat Protoc. 16:4692. PubMed
  350. Lee HY, et al. 2021. Curr Protoc. 1:e272. PubMed
  351. Mujal AM, et al. 2022. Cancer Immunol Res. 10:403. PubMed
  352. Hering L, et al. 2020. Front Immunol. 1.747222222. PubMed
  353. Korin B, et al. 2020. Sleep. :43. PubMed
  354. Santopaolo M, et al. 2021. Front Immunol. 609406:12. PubMed
  355. Donlan AN, et al. 2021. JCI Insight. 6: . PubMed
  356. Lisk C, et al. 2021. Front Immunol. 12:624197. PubMed
  357. Hosking M, Flynn C, Whitton J 2016. PLoS Pathog. 12: 1005861. PubMed
  358. Bryan AF, et al. 2020. Nucleic Acids Res. 48:2924. PubMed
  359. Sontheimer-Phelps A, et al. 2019. Cell Mol Gastroenterol Hepatol. 9:507. PubMed
  360. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  361. Eckert EC, et al. 2020. Mol Ther Oncolytics. 0.710416667. PubMed
  362. Chakraborty A, et al. 2022. Methods Mol Biol. 2442:565. PubMed
  363. Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed
  364. Kiesel VA, et al. 2022. Front Oncol. 12:767479. PubMed
  365. Gutierrez-Prat N, et al. 2022. Life Sci Alliance. 5:. PubMed
  366. Viant C, et al. 2020. Cell. 183:1298. PubMed
  367. Heckler M, et al. 2021. Cancer Discov. Online ahead of prin. PubMed
  368. Maller O, et al. 2020. Nat Mater. 20:548. PubMed
  369. Gaebler C, et al. 2020. bioRxiv. . PubMed
  370. Shimada BK, et al. 2020. Immunohorizons. 0.55625. PubMed
  371. Jeffery H, et al. 2017. Clin Exp Immunol. 10.1111/cei.12940. PubMed
  372. Wachowska M, et al. 2020. Cancer Immunol Immunother. 69:1101. PubMed
  373. Farrand K, et al. 2022. Curr Protoc. 2:e482. PubMed
  374. Qin J, et al. 2020. Cancer Immunol Res. 8:1426. PubMed
  375. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  376. Kastenschmidt JM, et al. 2021. Cell Rep. 35:108997. PubMed
  377. Kerdidani D, et al. 2022. J Exp Med. 219:. PubMed
  378. Sibler E, et al. 2022. Cancers (Basel). 14:. PubMed
  379. Spath S, et al. 2022. iScience. 25:104998. PubMed
  380. Chou DB, et al. 2020. Nat Biomed Eng. 0.440277778. PubMed
  381. Gangoso E, et al. 2021. Cell. 184:2454. PubMed
  382. Sibler E, et al. 2021. Cells. 10:. PubMed
  383. Clutton G, et al. 2016. Sci Rep. 6:30749. PubMed
  384. Binnewies M, et al. 2019. Cell. 177:556. PubMed
  385. Muchowicz A, et al. 2017. Eur J Cancer. 10.1016/j.ejca.2017.06.004. PubMed
  386. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
  387. Patterson DG, et al. 2021. J Immunol. 207:1798. PubMed
  388. Zhang N, et al. 2022. Front Immunol. 13:926368. PubMed
  389. Cho A, et al. 2022. J Exp Med. 219:. PubMed
  390. Celias DP, et al. 2022. STAR Protoc. 3:101464. PubMed
  391. Erens C, et al. 2022. Biomedicines. 10:. PubMed
  392. Zhou P, et al. 2022. Sci Transl Med. :eabi9215. PubMed
  393. Sauler M, et al. 2022. Nat Commun. 13:494. PubMed
  394. Guarnaccia AD, et al. 2021. STAR Protoc. 2:101000. PubMed
  395. Zhang L, et al. 2021. Mol Ther. 29:744. PubMed
  396. Gamradt S, et al. 2021. iScience. 24:103312. PubMed
  397. Li H, et al. 2021. Signal Transduct Target Ther. 6:389. PubMed
  398. Goddery EN, et al. 2021. Front Immunol. 12:726421. PubMed
  399. Xie Z, et al. 2020. Light Sci Appl. 9:161. PubMed
  400. Dar HH, et al. 2021. Redox Biol. 45:102045. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
NA

Related FAQs

I am concerned about the spillover I am observing from the Zombie dye into its neighboring channels.
Rule of thumb with Zombie dyes is to titrate them down as much as possible to fit your application. This should potentially help with spillover. Secondly, Zombie positive events represent dead cells and are typically gated out from analysis.
How does the performance of your Zombie dye compare with competitors?

Zombie dyes have been tested against other leading competitors' fixable viability kits and given comparable results. We also highly recommend that you titrate down the amount of each dye used in order to best match the negative signals of your unstained sample and MFI- (mean fluorescence intensity) stained samples.

Can I use methanol/ethanol for fixation after using a Zombie dye?

Yes, most fixation reagents are fine to be used with Zombie dyes. However, it should be noted that Zombie dyes can still be sensitive to reactive oxygen species. Light exposure or reagents with hydrogen peroxide can lead to free radical formation, affecting fluorescence.

Can Zombie be used to determine bacteria, yeast viability?
We have not tested in house bacterial or yeast viability using Zombie dyes. It is not clear whether the difference between surface and intracellular signals will be significantly different in case of non mammalian cells.
Can I use Zombie with cells suspension containing serum?
Serum is full of proteins which will sequester the dye and thereby reducing its effective concentration. The basic rule of thumb with zombie is to titrate it based on your specific condition. Titration also helps reduce the background and spillover into other channels.
Can I use Zombie dyes for microscopy?

Zombie dyes tested in-house for microscopy applications will display data on the product technical datasheet. It should be noted that Zombie dyes may not work for dead cell discrimination in every microscopy application. Important considerations that may impact analysis are determining the signal level that constitutes a dead cell and identifying the proper plane to observe the dead cells.

Why can't I fix my cells prior to using Zombie dyes?

The fixation process can contort and alter the membrane of cells, effectively rendering them dead. Since the ability of the Zombie dyes to stain dead cells is correlated with cell permeability, your results may no longer be a valid representation of dead versus live cells.

Can I use Zombie dyes to detect apoptotic cells?

Yes, Zombie dyes can be used with apoptosis markers, such as Annexin V or Apotracker™ (shown below), to discriminate live, apoptotic, and dead cells.

One day-old C57BL/6 mouse thymocytes were stained with Apotracker™ Tetra Alexa Fluor® 647 and Zombie™ YG581. Zombie-dim/Apotracker™-positive cells are apoptotic, while double-positive cells are dead. Live cells are negative for both markers.

How should I store Zombie dyes?

Store the Zombie dye kit at -20°C upon receipt. Do not open vials until needed. Once DMSO is added, use immediately or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.

Go To Top Version: 7    Revision Date: 12.18.2024

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account